Palisade Bio director awarded 592,300 RSUs

Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares.

Rhea-AI Filing Summary

Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 10, 2026, Wei received a grant of 592,300 RSUs of Palisade Bio common stock at no cash cost.

The filing also shows 20,200 RSUs converting into the same number of common shares as they vested on June 10, 2026. One line reports 613,355 common shares held directly after the RSU vesting, and another reports 593,155 shares after the new RSU grant. The RSU awards are subject to service-based vesting over three annual installments tied to future stockholder meetings or specified anniversaries, so Wei must remain in service for full delivery of shares.

Insider Trade Summary

20,200 shares exercised/converted

Exercise 3 txns

Insider Wei Binxian

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	20,200	$0.00	$0.00
Grant/Award	Common Stock	592,300	$0.00	$0.00
Exercise	Common Stock	20,200	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 40,400 contracts (Direct); Common Stock — 613,355 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
2. F2. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.
3. F3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

Key Figures

RSUs granted: 592,300 RSUs RSUs vested: 20,200 RSUs Shares after vesting line: 613,355 shares +4 more

7 metrics

RSUs granted 592,300 RSUs Grant to director on June 10, 2026

RSUs vested 20,200 RSUs Vested and converted into common stock on June 10, 2026

Shares after vesting line 613,355 shares Common stock held directly following RSU vesting transaction

Shares after grant line 593,155 shares Common stock held directly following RSU grant entry

Exercise price per share $0.0000 per share Reported for RSU-related common stock acquisitions

Exercise transactions 1 derivative exercise, 20,200 shares transactionSummary exerciseCount and exerciseShares

Total acquire-type transactions 3 transactions transactionSummary acquireCount

Key Terms

Restricted Stock Units, service-based vesting, annual installments, contingent right, +1 more

5 terms

Restricted Stock Units financial

"The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

service-based vesting financial

"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."

annual installments financial

"The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments..."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

grant, award, or other acquisition regulatory

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palisade Bio (PALI) director Binxian Wei report in this Form 4?

Director Binxian Wei reported equity compensation transactions, including a grant of 592,300 restricted stock units and the vesting of 20,200 RSUs into common shares, all dated June 10, 2026, with no cash paid per share.

How many RSUs were granted to Palisade Bio (PALI) director Binxian Wei?

The Form 4 shows a grant of 592,300 restricted stock units to director Binxian Wei. Each RSU represents a contingent right to receive one share of Palisade Bio common stock, subject to service-based vesting conditions over multiple years.

What RSUs vested for Palisade Bio (PALI) director Binxian Wei on June 10, 2026?

20,200 previously granted RSUs vested on June 10, 2026, converting into 20,200 shares of Palisade Bio common stock. These RSUs were part of a service-based award that vests in three equal annual installments tied to continued service.

What are the vesting terms of Binxian Wei’s new RSU grant at Palisade Bio (PALI)?

The new RSU grant vests in three equal annual installments. The first installment vests on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, conditioned on Wei’s continuous service with Palisade Bio.

How many Palisade Bio (PALI) shares does Binxian Wei hold after these transactions?

The Form 4 lists two post-transaction balances: 613,355 common shares after the RSU vesting transaction and 593,155 common shares after the RSU grant entry. Both figures reflect direct ownership reported in the filing.

Did Palisade Bio (PALI) director Binxian Wei buy or sell shares on the open market?

The Form 4 does not report any open-market purchases or sales. It shows RSU grants and RSU vesting into common shares at a transaction price of $0.0000 per share, typical for equity compensation, rather than market trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wei Binxian

(Last) (First) (Middle)

C/O PALISADE BIO, INC.

4600 SOUTH SYRACUSE STREET, SUITE 900

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A(1)		592,300	A	(1)	593,155	D
Common Stock	06/10/2026		M(2)		20,200	A	(2)	613,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	06/10/2026		M			20,200	(3)	(3)	Common Stock	20,200	$0	40,400	D

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.

2. The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.

3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.

	/s/ Ryker Willie, Attorney-in-Fact for Binxian Wei	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)